Protara Therapeutics
TARA
27 hedge funds and large institutions have $19.6M invested in Protara Therapeutics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 8 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0% more funds holding
Funds holding: 27 → 27 (0)
0.35% less ownership
Funds ownership: 1.47% → 1.12% (-0.35%)
3% less capital invested
Capital invested by funds: $20.3M → $19.6M (-$653K)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$75.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$56.6K |
| 3 |
RWM
Ritholtz Wealth Management
New York
|
+$53K |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
+$41K |
| 5 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$469K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$84K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$48K |
| 4 |
Renaissance Technologies
New York
|
-$31.4K |
| 5 |
VF
Virtu Financial
New York
|
-$28K |
TARA Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2018, worth a combined $19.6M — down 3.2% from $20.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TARA positions and 8 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $75.5K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $469K sold.
- 27 institutional investors held Protara Therapeutics (TARA) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $19.6M of Protara Therapeutics stock for Q4 2018, down 3.2% quarter-over-quarter.
- 9 funds opened new Protara Therapeutics positions in Q4 2018 and 8 closed out, a net change of +1 holder.
- The largest Protara Therapeutics buyer in Q4 2018 was Morgan Stanley, an estimated $75.5K added.
- The largest Protara Therapeutics seller in Q4 2018 was Perceptive Advisors, an estimated $469K sold.
Based on aggregated 13F filings for Q4 2018.